Medicine & Health

Washington University School of Medicine is joining the National Institutes of Health (NIH)’s Bridge2AI program, an estimated $130 million initiative. One project aims to develop a framework for using artificial intelligence to diagnose disease based on the sound of patients’ voices.

Washington University School of Medicine researchers have found a new druggable pathway, in mice, that potentially could be used to help prevent Alzheimer’s dementia.

The Tracy Family SILQ Center for Neurodegenerative Biology has been established at the School of Medicine. The center aims to help researchers discover, study and validate biomarkers of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with a goal of identifying new drug targets and creating better diagnostic and prognostic tests.

A research group led by Rohit Pappu in the McKelvey School of Engineering and Anthony Hyman at the Max Planck Institute have discovered a new, relevant level of structure in cells.

Three of four blood tests used to identify people in early stages of Alzheimer’s disease perform differently in Black individuals compared to white individuals, according to a new study from Washington University School of Medicine. Such differences may put Black patients at risk of misdiagnosis.

Researchers at Washington University School of Medicine have discovered that targeting astrocytes reduces tau-related brain damage and inflammation in mice, a finding that could lead to better therapies for Alzheimer’s and related tauopathies.

New research from Washington University School of Medicine shows that this novel MRI approach can identify brain cell damage in people at early stages of Alzheimer’s, before tissue shrinkage is visible on traditional MRI scans.

School of Medicine researchers are launching a phase 2 clinical trial to study whether using medication to treat sleep problems in older adults can reduce signs of early Alzheimer’s disease.

Using mass spectrometry, Washington University School of Medicine researchers have developed a blood test that is up to 93% accurate at identifying people at risk of Alzheimer’s dementia. The findings suggest that the test should be considered for routine screening and diagnosis.

Beau M. Ances, MD, PhD, the Daniel J. Brennan Professor of Neurology at the School of Medicine, recently received the Shining Star Award from the Down Syndrome Association of Greater St. Louis.